Trial Profile
Phase 1 Study Of SNX-5422 Mesylate In Adults With Refractory Solid Tumor Malignancies And Lymphomas.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 May 2012
Price :
$35
*
At a glance
- Drugs SNX 5422 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 16 May 2012 Company (Esanex) added as reported by ClinicalTrials.gov.
- 26 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Aug 2010 Planned end date changed from 1 Jul 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.